The Motley Fool
12 Oct 2025, 13:45 UTC · 51w ago
Verdict
Source says Buy. We score NTLA +0.90 across four claims.
Score confirms the headline.
Buy
Rating stated in the headline
+0.90strongly bullish
More positive than 95% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Intellia Therapeutics is pursuing the first-ever approved single-dose, in vivo CRISPR therapy via its programs for hereditary angioedema and ATTR amyloidosis.
So whatA successful shift to in vivo editing would be a fundamental breakthrough in gene therapy, potentially re-rating the entire sector's valuation.
More positive than 99% of claims this week
Vertex Pharmaceuticals reported $30 million in second-quarter 2025 sales for Casgevy, indicating the first approved gene-editing treatment is gaining market traction.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 93% of claims this week
Casgevy administration is scaling, with 75 hospitals/clinics cleared and approximately 115 patients having started treatment by mid-2025.
More positive than 79% of claims this week
Intellia Therapeutics expects topline Phase 3 results for its hereditary angioedema treatment in the first half of 2026.
More positive than 66% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
Advancing two key CRISPR programs toward pivotal readouts with potential for breakthrough in vivo therapy approval.
More positive than 88% of ticker scores this week
The company is seeing growth in Casgevy sales and has promising pipeline candidates like CTX112.
More positive than 88% of ticker scores this week
Reported a sharp uptick in Casgevy sales and is successfully commercializing the first gene-editing treatment.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
6h ago
−46.7%
Price is moving against the score
$13.07 vs $24.52 close before publication (Oct 10) · not market-adjusted
NTLA chart →
